86 results about "Synovitis" patented technology

The invention relates to the technical field of pharmaceutical chemicals, and discloses sequential drug release liposome hydrogel and a preparation method and application thereof, and the preparation method of the liposome hydrogel comprises the following steps: step 1, preparation of drug-loaded positive charge liposome; step 2, preparing phenylboronic acid modified polysaccharide; and step 3, carrying out vortex mixing on the drug-loaded positive charge liposome solution, the phenylboronic acid modified polysaccharide hydrogel precursor powder and the spermidine solution to obtain the liposome hydrogel. According to the sequential drug release liposome hydrogel as well as the preparation method and the application thereof, the liposome hydrogel is prepared by taking high-molecular hyaluronic acid and phenylboronic acid as main raw materials, and the liposome hydrogel has microenvironment responsiveness and time-space characteristics of drug release, and can be used for treating osteoarthritis in an environment with active oxygen increase, so that the drug release effect is good, and the drug release effect is good. The functions of early-stage anti-inflammation and continuous cartilage regeneration are achieved by sequentially releasing double drugs, synovitis can be effectively relieved, cartilage regeneration can be promoted, and the compound can be used for preparing drugs for treating osteoarthritis.

The invention relates to the field of osteoarthritis drug treatment, in particular to application of RuO2 nano-enzyme in preparation of a drug for treating osteoarthritis, and particularly relates to knee osteoarthritis. The RuO2 nano-enzyme disclosed by the invention is prepared according to the following method: carrying out incubation deposition on Cu2O sphere nano-particles and RuCl3 to obtain Cu2O and RuO2, and etching Cu2O and RuO2 spheres to obtain the RuO2 nano-enzyme. The RuO2 nano-enzyme provided by the invention is a hollow RuO2 nano-enzyme sphere, and after the RuO2 nano-enzyme is horizontally used in an animal body for intervention, the hollow RuO2 nano-enzyme sphere can be used as a hollow RuO2 nano-enzyme sphere; the RuO2 nano-enzyme can effectively delay the development of knee osteoarthritis of a mouse knee osteoarthritis model caused by medial meniscus instability (DMM), improve the pain condition and movement function of a DMM modeling mouse, reduce the gonarthromeningitis degree and relieve knee joint cartilage degeneration and injury, and the effectiveness of the RuO2 nano-enzyme in delaying the knee osteoarthritis disease is further proved. The invention provides a novel method for treating knee osteoarthritis, and has strong practicability and application prospect.

A weft yarn for an artificial ligament (1), a weft yarn preparation method, and an artificial ligament (1). The artificial ligament (1) is of a round rod structure; a first woven part (102), an in-joint free filament part (103), and a second woven part (104) which are sequentially connected are formed in the round rod structure in the axial direction thereof; the in-joint free filament part (103) comprises a plurality of weft yarns (201), and the weft yarns (201) extend in the axial direction of the round rod structure; and each weft yarn (201) has a fineness of 1000 D-3000 D / 1-100 F, and a mechanical strength of 75-300 N. By increasing the mechanical strength of a single yarn formed in the in-joint free filament part (103) of the artificial ligament (1), the number of yarns in the in-joint free filament part (103) is decreased. The present invention can eliminate a knee joint synovial membrane inflammatory response caused by chippings of the artificial ligament (1) in the reconstruction process of the artificial ligament (1), reduce the degree of contact adhesion between the in-joint free filament part (103) and the tissue, reduce the probability of adhesion, and solve the clinical problems of the inflammatory response and the prolonged surgery time which are caused by difficult removal due to adhesion of the free filaments and the tissue in the revision surgery.

The invention discloses a small molecule peptide and an application thereof. The small molecule peptide is TYVPKAF. The small molecule peptide TYVPKAF is screened from pilose antler for the first time, and the small molecule peptide TYVPKAF is suitable for oral administration, high in bioavailability, high in in-vivo efficacy, strong in selectivity and free of toxic and side effects. The small molecule peptide TYVPKAF provided by the invention has the advantages that the expression levels of MMP13 and cGAS are inhibited in a targeted manner, cartilage and lower bone injury are repaired, synovitis is relieved, and a new strategy is provided for treatment of osteoarthritis (OA). According to the small molecule peptide TYVPKAF, bone formation is promoted by inhibiting the Fap expression level, so that the healing process of bone defects is accelerated, and a new strategy is provided for treatment of the bone defects.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention is applicable to the technical field of medicine, and provides application of MgAl-LDH in preparation of a medicine for treating joint inflammation, LDH / RH-Gel for joint cavity injection is prepared by taking MgAl-LDH (magnesium aluminum hydrotalcite) as a carrier and carrying RH with anti-inflammatory and cartilage repair activity and combining with temperature-sensitive gel (Gel) by utilizing the advantages of joint cavity injection administration. The preparation is good in biological safety, the solubility of the RH is remarkably improved, and the residence time of the RH in an articular cavity is prolonged; the inflammatory response and cartilage loss are remarkably reduced, the disease progress is delayed, and the OA is effectively treated. The scheme is also suitable for delivery of joint inflammation treatment drugs such as non-steroidal anti-inflammatory drugs, hormone drugs, biological factors and monoclonal antibodies. And the MgAl-LDH can also form a composite carrier with other gels. The traditional Chinese medicine composition is expected to be used for treating arthritis diseases such as rheumatism, rheumatoid arthritis, osteoarthritis and synovitis.

This invention relates to the treatment of osteoarthritic pain, or pain associated with osteoarthritis, and particularly for LINK_TSG6 polypeptide for use in the treatment of osteoarthritic pain. Osteoarthritis is caused by the deterioration of cartilage in joints and is characterised by pain and a loss of mobility in the affected joints. Osteoarthritic pain results from multiple factors including bone marrow lesions, sub-articular bone attrition, synovitis, effusion and innervation of usually insensitive tissues. LINK_TSG6 is a short recombinant peptide comprising the LINK module of human TSG-6.

The invention relates to application of a miR-155-5p inhibitor delivered by an exosome of a targeted synovitis macrophage to treatment of osteoarthritis, and belongs to the technical field of biological medicines. According to the scheme, the exosome drug delivery system for targeting the synovial inflammatory macrophages in the osteoarthritis, which contains the miR-155-5p inhibitor, is prepared through a genetic engineering technology, so that the exosome derived from stem cells is targeted to inflammatory synovial tissues, and damaged cartilage tissues are repaired and inflammation is resisted based on the stem cell exosome; compared with the prior art, the application has the advantages that the combined action of inhibiting the osteoarthritis injury and inhibiting the miR-155-5p so as to resist synovitis is realized, the osteoarthritis injury repair can be better applicable, a new scheme for treating the osteoarthritis is provided, a support is provided for clinical transformation, and the application value is extremely high.

The present invention relates to the field of traditional Chinese medicine analysis technology, and more particularly to a method for constructing a characteristic spectrum for synovitis capsules and its application. The method comprises the following steps: 1. preparing a reference solution; 2. preparing a test solution; 3. determining the assay conditions; and 4. importing the chromatogram into a traditional Chinese medicine spectrum to generate a control characteristic spectrum. This characteristic method identifies 13 characteristic peaks, demonstrates high repeatability and precision, and comprehensively and comprehensively displays the chemical composition characteristics of synovitis capsules, enabling comprehensive control of the capsule's pharmaceutical quality.

The invention belongs to the technical field of medicines, and particularly relates to application of BAY-069 in preparation of a medicine for treating rheumatoid arthritis. Through metabonomics research, the inventor finds that the metabolic enzyme BCAT2 is remarkably highly expressed in synovial tissues of an active-stage RA patient and is relatively low in expression in synovial tissues of a remission-stage RA patient. The high expression of the metabolic enzyme BCAT2 is closely related to synovitis and bone destruction. The BAY-069 as a BCAT2 inhibitor can significantly reduce the score of joint inflammation, reduce synovitis and bone destruction, and effectively reduce bone loss. The invention provides an innovative RA metabolism targeted treatment strategy which has high safety and strong targeting property.

The invention belongs to the technical field of traditional Chinese medicine compositions, and provides a powder decoction plaster for treatment and health care of rheumatism bone diseases and a preparation method thereof, the powder decoction plaster comprises the following raw materials by mass: 20-25 parts of ox horn slices, 10-25 parts of light wheat, 20-25 parts of yellow ginger, 20-25 parts of dried ginger, 2-10 parts of notopterygium root, 3-10 parts of sichuanese peppercorn, 0.1-0.5 part of safflower, 0.1-2 parts of cortex acanthopanacis, 0.1-0.5 part of licorice, 1-5 parts of rhizoma cibotii, and 1-5 parts of cortex dictamni. The traditional Chinese medicine disclosed by the invention is decocted into ointment to be applied to an affected part, has the effects of promoting rehabilitation and health, and is used for treatment and health care of lumbar disc herniation, cervical spondylosis, fracture, arthritis, synovitis, hyperostosis, scapulohumeral periarthritis, lumbar disc herniation, sprain and contusion and soft tissue contusion.

The invention provides pain-relieving and stasis-dissipating powder for treating soft tissue and gout, and relates to the technical field of traditional Chinese medicines. The pain-relieving and stasis-dissipating powder for treating soft tissue and gout is prepared from cortex phellodendri, fructus gardeniae, frankincense, myrrh, radix et rhizoma rhei, radix angelicae sinensis, radix angelicae and borneol. The pain-relieving and blood stasis-dissipating powder has the effects of promoting blood circulation to remove blood stasis, relieving swelling and pain, clearing heat, eliminating dampness, removing blood stasis and promoting tissue regeneration, and has a remarkable curative effect on early fracture, soft tissue injury, gout, synovitis and the like.

The present application relates to the fields of medicine, modernization of traditional Chinese medicine and drug delivery, and specifically relates to a macrophage-derived exosome loaded with aconite decoction extract, a preparation method thereof and application thereof in preparation of a drug for preventing and treating osteoarthritis. The effective component of the drug preparation is macrophage-derived exosome loaded with aconite decoction extract, which includes low-loading preparation WTDL-Exos and high-loading preparation WTDH-Exos and contains pharmaceutically acceptable excipients. The macrophage-derived exosome is preferably derived from mouse macrophage RAW264.7 and is extracted through differential centrifugation and ultracentrifugation; the aconite decoction extract is prepared from prepared monkshood, astragalus, honeyed licorice, ephedra and peony, and the concentration of the aconite decoction mother liquor is 10 mg / mL; the drug-loaded exosome is obtained by co-incubation of the aconite decoction extract and the macrophage-derived exosome and purification, and the loading rate is about 20%. In vitro tests show that WTD-Exos has no obvious effect on cell survival rate and is basically non-cytotoxic. Western blot detection in animal experiments shows that the drug preparation can down-regulate the expression of MMP-13 and TNF-α in synovial tissue and up-regulate the expression of type II collagen, thereby improving joint synovial inflammation and protecting joint cartilage. The drug preparation can be used for preparing a drug for preventing and treating osteoarthritis.

The invention relates to the technical field of biological medicines, in particular to application of pellicine to preparation of a medicine for treating rheumatoid arthritis. The in-vivo echinaceine can interfere with the pathological process of rheumatoid arthritis in a multi-dimensional manner by inhibiting proliferation, migration and invasion of MH7A cells induced by TNF-alpha, promoting apoptosis of the MH7A cells and down-regulating protein expression of IL-6, MMP-3 and MMP-9. In vivo, the pellicine can relieve joint swelling, synovitis and cartilage injury of adjuvant arthritis rats by inhibiting protein expression of RF, IL-6, MMP-3 and MMP-9. The pellicine has the prospect of being developed into the medicine for treating rheumatoid arthritis.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traumatology crymodynia traditional Chinese medicine composition and a preparation method and application thereof. The cold pain traditional Chinese medicine composition for the department of traumatology comprises the following components in parts by weight: 6-10 parts of cortex cercis chinensis, 6-10 parts of fructus viticis, 1-3 parts of radix salviae miltiorrhizae, 1-3 parts of rhizoma wenyujin concisum, 1-2 parts of fructus forsythiae, 1-3 parts of flos caryophylli, 1-3 parts of cortex cinnamomi and 1-3 parts of lamiophlomis rotata. After a mouse with knee osteoarthritis (KOA) is intervened with the traumatology crymodynia patch prepared by the method, mouse synovial inflammation is relieved, serum inflammatory factors and pain media are reduced, crymodynia sensitivity threshold value is increased, up-regulation of relevant indexes of crymodynia sensitivity, fibrosis and nerve germination as well as relevant index protein and gene expression level of training immunity is remarkably reversed, and the traumatology department crymodynia patch can be used for treating knee osteoarthritis (KOA). The traditional Chinese medicine composition can significantly improve synovitis and crymodynia sensitivity of KOA mice, adopts channel-warming and blood-activating medicines, has a significant curative effect in clinical application, and especially has a relatively significant effect on the symptom of crymodynia sensitivity of KOA patients.

The application discloses a multi-component synovitis treatment composition based on repairing cartilage tissue and application thereof, and relates to the technical field of biological medicine, and the composition is composed of glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone and graded molecular weight sodium hyaluronate; the application precisely compounding the graded molecular weight sodium hyaluronate with the glucosamine hydrochloride, the chondroitin sulfate and the dimethyl sulfone according to weight parts, constructs a gradient slow-release and target delivery system of synovitis lesions, specifically inhibits the activity of hyaluronidase in the inflammatory joint cavity by using the dimethyl sulfone, greatly reduces the degradation of the sodium hyaluronate, prolongs the residence time of the active ingredients at the lesion site, realizes immediate analgesia and relieves joint stiffness by quickly forming a lubricating protective film by the high molecular weight sodium hyaluronate, the medium and low molecular weight sodium hyaluronate penetrates the synovial membrane barrier and carries the cartilage repair components to enrich in the cartilage defect area, and the synergistic effect of the components is realized.

Compositions for treatment or prevention of synovitis contain a therapeutically effective amount of at least one of oleuropein, rutin or curcumin and preferably contain at least oleuropin. Methods for treatment or prevention of synovitis include administering such compositions. The compositions can additionally include one or more of quercetin, hydroxytyrosol or vitamin D.

The present disclosure provides improved methods, therapeutic regimens, and systems for treating a disease associated with a pituitary malignancy in a subject, such as treating Cushing Syndrome, or treating one or more symptoms of Cushing Syndrome in subjects, through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods. The present disclosure also relates to compositions for use and methods in treating synovial inflammation in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression. The present disclosure also relates to compositions for use and methods in treating degenerative joint disease, joint inflammation, and manifestations thereof in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression.

The invention discloses a multi-modal data fusion-based rheumatoid arthritis early-stage AI intelligent diagnosis system, belongs to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, RA early-stage diagnosis lags behind, the rate of missed diagnosis of serum negative patients is high, and risk assessment lacks quantitative standards. Comprising a multi-source data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic time sequence model and a risk assessment module which are connected in sequence, according to the system provided by the invention, a dynamic tracking model of serological change-synovial inflammation-bone structure change is innovatively constructed, and an RA diagnosis window is advanced compared with that of a traditional method (depending on clinical symptoms) by capturing time sequence correlation of the serological change, the synovial inflammation and the bone structure change; aiming at the diagnosis difficulty of serum-negative RA, the system realizes great improvement of diagnosis performance through deep fusion of multi-modal features, serological core indexes, ultrasonic synovial dynamic features and X-ray bone microscopic features.

The invention provides a rheumatoid arthritis-simulated synovitis in-vitro model and a construction method thereof, and according to the method, a three-channel micro-fluidic chip is used as a carrier to carry out 3D co-culture of synovial fibroblasts, macrophages and vascular endothelial cells. According to the construction method provided by the invention, 3D culture of the three cells can be realized, and a real result closer to that in vivo can be provided for subsequent drug screening and drug efficacy evaluation. According to the construction method provided by the invention, under the condition of not additionally adding stimulating factors, the three cells are cultured at the same time, the effect of simulating synovitis in vitro is achieved through the interaction among the cells, and the construction method has important significance for deeply understanding the effects of different cells in diseases.

The present application relates to the field of medicine, and more particularly to a kind of pharmaceutical composition, and the pharmaceutical preparation and application comprising the pharmaceutical composition, the pharmaceutical composition includes ligustrazine nanoparticle and Shujin Huoluo compound composition, ligustrazine nanoparticle includes carrier and ligustrazine loaded in carrier, by ligustrazine nanoparticle and Shujin Huoluo compound composition combined use, play synergistic effect, significantly improve the treatment effect to OA.In addition, both combined use shows significant curative effect in reducing synovial inflammation and repairing chondrocyte apoptosis and reducing pain-related biological indicators, which is of great significance to improve the quality of life of OA patients.

The invention relates to the technical field of body conditioning medicines, in particular to a medicine formula for conditioning a body movement system and a preparation process of the medicine formula. Comprising a main material and an auxiliary material, the main material is prepared by mixing the following raw materials by weight: 15-24 g of white peony root, 2-8 g of licorice, 4-12 g of achyranthes bidentata, 2-8 g of safflower, 5-15 g of dogwood, 5-12 g of prepared rehmannia root, 5-15 g of eucommia ulmoides, 2-10 g of fennel, 4-15 g of fructus aurantii and 15-25 g of folium artemisiae argyi; the auxiliary material is prepared by mixing the following raw materials by weight: 3-7 g of coix seed powder, 1-3 g of small red bean powder, 1-3 g of pea powder, 1-3 g of buckwheat powder, 1-3 g of Chinese yam powder, 1-3 g of soybean powder, 1-3 g of hyacinth bean powder, 8-12 g of Chinese wolfberry and 8-12 g of red dates. The formula has the beneficial effects that the formula is scientifically prepared, the nutrition is balanced, and diseases such as cervical spondylosis, chest, neck, waist and leg pains (chest, neck, waist and legs), protrusion of intervertebral disc, ankylosing spondylitis, arthritis, tennis elbow, rheumatic arthritis, femoral head necrosis, numbness of limbs, arthralgia, synovitis, knee effusion, meniscus injury, hyperostosis, sciatica and varicosity can be conditioned.

A liposome encapsulating adenosine is provided herein. Liposomes can be formed by a combination of sphingomyelin or sphingomyelin and 1,2-dimyristoyl-sn-glycerol-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycerol-3-phosphoglycerol (DMPG) or a combination of sphingomyelin, DMPG and DMPC. Liposomes encapsulating adenosine can be used to induce cartilage regeneration, treat osteoarthritis, relieve joint pain, and / or slow down, prevent and / or reverse the progressive structural tissue damage associated with osteoarthritis, or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis and / or synovitis. Liposomes can release adenosine for up to two weeks.

The invention relates to the technical field of medicines, in particular to application of nardosinone in preparation of a medicine for treating rheumatoid arthritis. In-vivo animal experiments and in-vitro cell experiments prove that Nardosinone (Nar) has a treatment effect on synovitis caused by rheumatoid arthritis for the first time, and the action mechanism of Nardosinone (Nar) is preliminarily revealed. The invention provides a basis for exploring wide application of Nar in other inflammatory diseases which play a key role in mitochondrial autophagy, and provides a technical support for research and development of novel rheumatoid arthritis treatment medicines.

The application provides a construction method and a content determination method of a synovitis preparation characteristic spectrum, and belongs to the technical field of drug detection. The construction method is that a test sample solution is prepared by using the synovitis preparation, then acetonitrile-0.08-0.12wt% formic acid aqueous solution is used as a mobile phase, high performance liquid chromatography detection is carried out, the characteristic spectrum of the synovitis preparation is obtained, and the content of components in the synovitis preparation is further determined. The method can comprehensively cover the key active components of core medicinal materials in the prescription of the synovitis preparation, realizes the synchronous detection of multiple categories and multiple target components, and completely solves the defects of single quality control index and incomplete coverage in the prior art.

The invention discloses a Jinhuang powder external application paste and application thereof in preparation of drugs for treating gonitis synovitis, the external application paste is prepared from ten traditional Chinese medicines including turmeric, rheum officinale, golden cypress, radix angelicae, rhizoma arisaematis, pericarpium citri reticulatae, rhizoma atractylodis, mangnolia officinalis, liquorice and radices trichosanthis, honey, edible vegetable oil, paraffin oil and water through a specific emulsification process, the pH value is 6.0-7.0, and the viscosity is 3000-5000 mPa.s; standard random control clinical tests prove that the total effective rate of the external application ointment for treating gonarthromeningitis reaches 99.04%, the Lyshilm score is improved by 30.2 score, the VAS score is reduced by 5.39 score and is greatly superior to that of a diclofenac sodium control group, the adverse reaction occurrence rate is only 3.85%, the levels of serum TNF-alpha, IL-1beta and IL-6 and the synovial thickness can be greatly reduced, and the external application ointment has a good clinical application prospect. The method is suitable for K-L grading I-II and postoperative rehabilitation patients.

This invention relates to the field of traditional Chinese medicine preparations, and discloses a Tongli capsule and its preparation process, comprising the following raw materials: Eupolyphaga sinensis, processed Arisaema heterophyllum, vinegar-processed frankincense, vinegar-processed myrrh, dragon bone, Angelica dahurica, Lysimachia christinae, safflower, Notopterygium incisum, Angelica sinensis, Saposhnikovia divaricata, Cimicifuga foetida, Ligusticum chuanxiong, and Acorus tatarinowii; wherein, the raw materials are dried, pulverized, mixed, and then filled into capsule shells to form capsules. This Tongli capsule, using a total of fourteen traditional Chinese medicines as raw materials, follows the treatment principles of traditional Chinese medicine of dispelling wind and dampness, relaxing muscles and tendons, and promoting blood circulation and removing blood stasis. It has significant efficacy for late-stage fractures and joint dislocations, joint pain, synovitis, and other diseases caused by wind-cold-dampness obstructing the meridians. Furthermore, the capsule dosage form, with its uniform fine powder contents, makes it convenient to take, provides accurate dosage, has high bioavailability, and improves patient compliance. Compared to decoctions, capsules do not require decocting, making them easier to carry and store; compared to pills and powders, capsules can mask unpleasant odors of the medicine, and disintegrate rapidly, resulting in faster onset of action.

The embodiment of the invention provides ultrasonic equipment, a synovitis detection device, electronic equipment and a storage medium. The equipment comprises an ultrasonic probe and a processing device, and the ultrasonic probe is used for collecting a target ultrasonic image at a target joint; the processing device is used for recognizing an articular side bone area and a synovitis area from the target ultrasonic image and determining level information of synovitis based on the position relation between the synovitis area and the articular side bone area when the synovitis area is recognized, and the level information is used for indicating the severity of the synovitis; wherein the joint side bone area is the area where bones located on the two sides of the target joint are located, and the synovitis area is the area generated by synovial hyperplasia or the area generated by synovial hyperplasia combined with hydrops. According to the scheme, the workload of manually determining whether the synovitis area exists or not and determining the level information of the synovitis when the synovitis exists can be reduced, and the obtained information about the synovitis is more accurate.

To provide compositions and methods for preventing inflammatory diseases of joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of a ligament, synovitis, gout, and systemic lupus erythematosus.SOLUTION: A therapeutic anti-inflammatory composition for treating an inflammatory joint disease comprises a therapeutically effective amount of an IL-10 expression construct, and is administered by injection into an inflamed joint. The IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.SELECTED DRAWING: None

The invention discloses a dual-module delivery system and application thereof in preparation of a medicine for treating osteoarthritis or synovitis. Comprising an articular cavity drug delivery module 1 and an articular cavity drug delivery module 2, the module 1 is a nanoparticle or an exosome or a microsphere wrapping an aging cell scavenger, and the module 2 is a nanoparticle or an exosome or a microsphere wrapping an M2 polarization inducer; the compound is applied to the treatment medicine for osteoarthritis or synovitis, can target senescence synovial fibroblasts and M1 macrophages, combines senescence cell removal with a macrophage reprogramming mechanism, solves the problems of generation of senescence-related secretory phenotypes and inflammatory polarization of macrophages, and has a good application prospect in treatment of osteoarthritis or synovitis. By reducing SASP sources and inflammatory reactions at the same time, vicious circle of senescence-inflammation cascade reactions is broken, stability of the environment in joints is recovered, and the application prospect is extremely high.